BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 12911539)

  • 1. Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus.
    Calvani N; Satoh M; Croker BP; Reeves WH; Richards HB
    Kidney Int; 2003 Sep; 64(3):897-905. PubMed ID: 12911539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane.
    Richards HB; Satoh M; Jennette JC; Croker BP; Yoshida H; Reeves WH
    Kidney Int; 2001 Dec; 60(6):2173-80. PubMed ID: 11737591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane.
    Summers SA; Odobasic D; Khouri MB; Steinmetz OM; Yang Y; Holdsworth SR; Kitching AR
    Clin Exp Immunol; 2014 Jun; 176(3):341-50. PubMed ID: 24528105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus.
    Urbonaviciute V; Starke C; Pirschel W; Pohle S; Frey S; Daniel C; Amann K; Schett G; Herrmann M; Voll RE
    Arthritis Rheum; 2013 Jun; 65(6):1612-23. PubMed ID: 23450347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis.
    Savarese E; Steinberg C; Pawar RD; Reindl W; Akira S; Anders HJ; Krug A
    Arthritis Rheum; 2008 Apr; 58(4):1107-15. PubMed ID: 18383384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors.
    Clynes R; Calvani N; Croker BP; Richards HB
    Clin Exp Immunol; 2005 Aug; 141(2):230-7. PubMed ID: 15996187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane.
    Satoh M; Hamilton KJ; Ajmani AK; Dong X; Wang J; Kanwar YS; Reeves WH
    J Immunol; 1996 Oct; 157(7):3200-6. PubMed ID: 8816434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus.
    Richards HB; Satoh M; Shaw M; Libert C; Poli V; Reeves WH
    J Exp Med; 1998 Sep; 188(5):985-90. PubMed ID: 9730900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy.
    Summers SA; Hoi A; Steinmetz OM; O'Sullivan KM; Ooi JD; Odobasic D; Akira S; Kitching AR; Holdsworth SR
    J Autoimmun; 2010 Dec; 35(4):291-8. PubMed ID: 20810248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice.
    Richards HB; Satoh M; Jennette JC; Okano T; Kanwar YS; Reeves WH
    Clin Exp Immunol; 1999 Mar; 115(3):547-53. PubMed ID: 10193432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus.
    Hamilton KJ; Satoh M; Swartz J; Richards HB; Reeves WH
    Clin Immunol Immunopathol; 1998 Mar; 86(3):271-9. PubMed ID: 9557160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus.
    Satoh M; Weintraub JP; Yoshida H; Shaheen VM; Richards HB; Shaw M; Reeves WH
    J Immunol; 2000 Jul; 165(2):1036-43. PubMed ID: 10878381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin E2-mediated dysregulation of proinflammatory cytokine production in pristane-induced lupus mice.
    Chae BS; Shin TY; Kim DK; Eun JS; Leem JY; Yang JH
    Arch Pharm Res; 2008 Apr; 31(4):503-10. PubMed ID: 18449509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-complement factor H (CFH) autoantibodies could delay pristane-induced lupus nephritis.
    Li LL; Luan ZQ; Tan Y; Wang H; Yu XJ; Qu Z; Yu F; Chen M
    Immunol Res; 2023 Dec; 71(6):849-859. PubMed ID: 37322353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of mast cell-deficient W/Wv mice to pristane-induced experimental lupus nephritis.
    Lin L; Gerth AJ; Peng SL
    Immunol Lett; 2004 Feb; 91(2-3):93-7. PubMed ID: 15019275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted IgA Fc receptor I (FcαRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice.
    Liu C; Kanamaru Y; Watanabe T; Tada N; Horikoshi S; Suzuki Y; Liu Z; Tomino Y
    Clin Exp Immunol; 2015 Sep; 181(3):407-16. PubMed ID: 25907714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice.
    Yoshida H; Satoh M; Behney KM; Lee CG; Richards HB; Shaheen VM; Yang JQ; Singh RR; Reeves WH
    Arthritis Rheum; 2002 Aug; 46(8):2235-44. PubMed ID: 12209530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of haemorrhagic pulmonary capillaritis: another manifestation of Pristane-induced lupus.
    Chowdhary VR; Grande JP; Luthra HS; David CS
    Rheumatology (Oxford); 2007 Sep; 46(9):1405-10. PubMed ID: 17576695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D supplementation ameliorates arthritis but does not alleviates renal injury in pristane-induced lupus model.
    Correa Freitas E; Evelyn Karnopp T; de Souza Silva JM; Cavalheiro do Espírito Santo R; da Rosa TH; de Oliveira MS; da Costa Gonçalves F; de Oliveira FH; Guilherme Schaefer P; André Monticielo O
    Autoimmunity; 2019 Mar; 52(2):69-77. PubMed ID: 31088305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pristane-Accelerated Autoimmune Disease in (SWR X NZB) F1 Mice Leads to Prominent Tubulointerstitial Inflammation and Human Lupus Nephritis-Like Fibrosis.
    Gardet A; Chou WC; Reynolds TL; Velez DB; Fu K; Czerkowicz JM; Bajko J; Ranger AM; Allaire N; Kerns HM; Ryan S; Legault HM; Dunstan RW; Lafyatis R; Lukashev M; Viney JL; Browning JL; Rabah D
    PLoS One; 2016; 11(10):e0164423. PubMed ID: 27760209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.